Skip to main content
Equibles
MIRM logo

MIRM · Mirum Pharmaceuticals, Inc.

Track MIRM — free

Use MIRM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about MIRM

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$100.64 +1.87 (+1.89%) At close · Aug 14
Market Cap
$6.43B
Shares
64.93M

Mirum Pharmaceuticals, Inc. Earnings Call Transcripts

Every quarterly earnings call for Mirum Pharmaceuticals, Inc. (MIRM) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲275.6% $18.78M −$35.71M '22 Q3 22-11-09 ▲789.3% $27.91M −$36.43M '22 Q4 23-01-09 ▲145.1% $31.60M −$30.13M '23 Q1 23-05-04 ▲114.5% $37.50M −$74.04M '23 Q2 23-08-03 ▲154.1% $47.73M −$23.59M '23 Q3 23-11-02 ▲149.2% $69.55M −$35.66M '23 Q4 24-02-28 ▲119.1% $69.22M −$25.28M '24 Q1 24-05-08 ▲107.7% $77.88M −$24.64M '24 Q2 24-08-07 ▲89.4% $90.38M −$14.23M '24 Q3 24-11-12 ▲42.9% $99.41M −$23.79M '24 Q4 25-01-13 ▲61.2% $111.58M −$14.68M '25 Q1 25-05-07 ▲64.1% $127.78M −$5.86M '25 Q2 25-08-06 ▲47.2% $133.01M $2.90M '25 Q3 25-11-04 ▲49.8% $148.93M −$5.73M '25 Q4 26-02-25 ▲43.3% $159.88M −$790.15M '26 Q1 26-05-06 LATEST ▲37.9% $176.24M −$67.23M '26 Q2 26-08-05
Earnings call
FY26 · Q2
2026-08-05
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
Positive tone Velixabat PSC/VISTA regulatory delay Velixabat PBC/Vantage study Commercial sales and guidance raise
Revenue
$176.24M
▲ 37.9% YoY
Diluted EPS
$-1.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-05-19
H.C. Wainwright 4th Annual BioConnect Investor Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Mirum Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone ZalurgoCertid / FOP licensing Rare liver disease pipeline (PSC, hepatitis delta) Livmarly / PFIC commercial performance
Revenue
$159.88M
▲ 43.3% YoY
Diluted EPS
$-13.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Mirum Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone Pipeline and registrational readouts Volixibat VISTA study in PSC Pediatric cholestatic expansion (EXPAND)
Revenue
$148.93M*
▲ 49.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Mirum Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone LIVMARLI franchise (Alagille and PFIC) Volixibat VISTAS Phase IIb in PSC Pipeline expansion (EXPAND, MRM-3379 in Fragile X)
Revenue
$133.01M
▲ 47.2% YoY
Diluted EPS
$0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Mirum Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone Livmarli U.S. performance (PFIC, Alagille, new formulation) Volixibat VISTAS Phase IIb in PSC International Livmarli expansion (Europe, Japan via Takeda)
Revenue
$127.78M
▲ 64.1% YoY
Diluted EPS
$-0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Mirum Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Confident tone LIVMARLI performance and tablet launch Pipeline: Volixibat VISTAS in PSC Pipeline: Volixabat VANTAGE in PBC and EASL data
Revenue
$111.58M
▲ 61.2% YoY
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Mirum Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone OCA competition in PBC Livmarly EXPAND study (broader cholestatic pruritus) 2025 financial guidance
Revenue
$99.41M*
▲ 42.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Mirum Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone LIVMARLI commercial growth Volixibat pipeline (PBC/PSC) CHENODAL/CTX PDUFA
Revenue
$90.38M
▲ 89.4% YoY
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Mirum Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Revenue
$77.88M
▲ 107.7% YoY
Diluted EPS
$-0.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Mirum Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone PFIC label expansion Volixibat interim analysis LIVMARLI commercial growth
Revenue
$69.22M
▲ 119.1% YoY
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Mirum Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Confident tone LIVMARLI commercial growth Volixibat pipeline (VISTAS/VANTAGE) 2024 financial guidance
Revenue
$69.55M*
▲ 149.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Mirum Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Revenue
$47.73M
▲ 154.1% YoY
Diluted EPS
$-0.57
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Mirum Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Revenue
$37.50M
▲ 114.5% YoY
Diluted EPS
$-1.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Mirum Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Revenue
$31.60M
▲ 145.1% YoY
Diluted EPS
$-0.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Mirum Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Revenue
$27.91M*
▲ 789.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Mirum Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Revenue
$18.78M
▲ 275.6% YoY
Diluted EPS
$-1.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Mirum Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Revenue
$17.48M
▲ 58.9% YoY
Diluted EPS
$-0.84
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Mirum Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Revenue
$12.89M
Diluted EPS
$-1.17
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-09
Mirum Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Revenue
$3.14M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Mirum Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Revenue
$5.00M
Diluted EPS
$-1.55
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Mirum Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Revenue
$11.00M
Diluted EPS
$-1.45
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Mirum Pharmaceuticals, Inc. Q1 FY2021 Earnings Call
Revenue
$
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–23 of 23 earnings calls
Key facts CIK 1759425 CUSIP 604749101 13F (30d) 320 filings 314 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)